期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 20, 期 6, 页码 757-768出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2011.573785
关键词
A(3) adenosine receptor; asthma; cancer; IB-MECA; rheumatoid arthritis
资金
- National Institutes of Health [R01GM66189]
- USAMRMC [09065004]
- Hungarian Scientific Research Fund (OTKA) [CK 78275]
- NIH/NIAAA
Introduction: Adenosine is an endogenous nucleoside that accumulates in the extracellular space in response to metabolic stress and cell damage. Extracellular adenosine is a signaling molecule that signals by activating four GPCRs: the A(1), A(2A), A(2B) and A(3) receptors. Since the discovery of A(3) adenosine receptors, accumulating evidence has identified these receptors as potential targets for therapeutic intervention. Areas covered : A(3) adenosine receptors are expressed on the surface of most immune cell types, including neutrophils, macrophages, dendritic cells, lymphocytes and mast cells. A(3) adenosine receptor activation on immune cells governs a broad array of immune cell functions, which include cytokine production, degranulation, chemotaxis, cytotoxicity, apoptosis and proliferation. In accordance with their multitudinous immunoregulatory actions, targeting A(3) adenosine receptors has been shown to impact the course of a wide spectrum of immune-related diseases, such as asthma, rheumatoid arthritis, cancer, ischemia and inflammatory disorders. Expert opinion : Given the existence of both preclinical and early clinical data supporting the utility of A(3) adenosine receptor ligands in treating immune-related diseases, further development of A(3) adenosine receptor ligands is anticipated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据